IRIS
PEA, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.197
AS - Asia 6.340
EU - Europa 4.435
SA - Sud America 896
AF - Africa 120
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 5
Totale 29.014
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.028
SG - Singapore 3.081
CN - Cina 1.207
UA - Ucraina 1.138
BR - Brasile 719
HK - Hong Kong 670
DE - Germania 651
IT - Italia 622
SE - Svezia 493
VN - Vietnam 482
RU - Federazione Russa 354
TR - Turchia 302
FR - Francia 280
FI - Finlandia 237
IE - Irlanda 220
GB - Regno Unito 175
IN - India 145
CA - Canada 90
BD - Bangladesh 67
AR - Argentina 55
IQ - Iraq 52
KR - Corea 45
MX - Messico 44
JP - Giappone 43
BE - Belgio 40
NL - Olanda 40
ID - Indonesia 36
EC - Ecuador 35
ES - Italia 33
SA - Arabia Saudita 31
CZ - Repubblica Ceca 30
ZA - Sudafrica 30
CO - Colombia 25
EU - Europa 21
PL - Polonia 18
VE - Venezuela 18
EG - Egitto 17
PK - Pakistan 17
PH - Filippine 16
IR - Iran 15
LT - Lituania 14
MA - Marocco 14
UZ - Uzbekistan 14
CL - Cile 13
KE - Kenya 13
IL - Israele 12
CH - Svizzera 11
JO - Giordania 11
UY - Uruguay 11
AZ - Azerbaigian 10
RO - Romania 10
TH - Thailandia 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
AT - Austria 8
KZ - Kazakistan 8
MY - Malesia 8
PE - Perù 8
RS - Serbia 8
AL - Albania 7
BG - Bulgaria 7
BO - Bolivia 7
PT - Portogallo 7
DO - Repubblica Dominicana 6
ET - Etiopia 5
JM - Giamaica 5
NP - Nepal 5
TW - Taiwan 5
AU - Australia 4
KH - Cambogia 4
KW - Kuwait 4
LB - Libano 4
LV - Lettonia 4
OM - Oman 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
TG - Togo 4
BB - Barbados 3
CY - Cipro 3
EE - Estonia 3
GA - Gabon 3
HN - Honduras 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
PA - Panama 3
PS - Palestinian Territory 3
PY - Paraguay 3
SD - Sudan 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
BF - Burkina Faso 2
BH - Bahrain 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CM - Camerun 2
CR - Costa Rica 2
DK - Danimarca 2
DZ - Algeria 2
GE - Georgia 2
Totale 28.971
Salva come PNG Salva come JPEG
Città #
Fairfield 2.203
Woodbridge 1.561
Ashburn 1.437
Singapore 1.419
Chandler 1.139
Houston 1.091
Ann Arbor 962
Wilmington 839
Seattle 830
Cambridge 715
Hong Kong 658
Jacksonville 635
Dallas 605
Beijing 563
Dearborn 427
Boardman 349
San Jose 347
Izmir 271
Princeton 237
Dublin 219
Lauterbourg 217
Udine 194
Des Moines 174
Los Angeles 157
Ho Chi Minh City 129
San Diego 125
Redondo Beach 105
Hanoi 100
New York 89
Buffalo 87
Dong Ket 71
Munich 70
The Dalles 67
Helsinki 59
Orem 59
Falls Church 58
São Paulo 58
Redmond 57
Hefei 51
Santa Clara 48
Norwalk 43
Frankfurt am Main 40
Ogden 40
Tokyo 40
Brussels 39
Nanjing 36
Seoul 35
Council Bluffs 34
Grafing 33
Ottawa 30
Montreal 28
Chicago 27
Milan 27
Shanghai 27
Amsterdam 26
Brooklyn 26
Moscow 25
Denver 24
Phoenix 24
Brasília 23
London 23
Grugliasco 22
Guangzhou 22
Nuremberg 22
Rio de Janeiro 22
Kunming 20
Mumbai 20
Chennai 19
Johannesburg 19
Rome 18
Baghdad 17
Jinan 17
Warsaw 17
Brno 16
Belo Horizonte 15
Da Nang 15
Manchester 15
San Francisco 15
San Mateo 15
Trieste 15
Atlanta 14
Bologna 14
Curitiba 14
Quito 14
Biên Hòa 13
Dhaka 13
Düsseldorf 13
Haiphong 13
Jeddah 13
Wuhan 13
Boston 12
Piemonte 12
Riyadh 12
Toronto 12
West Jordan 12
Hyderabad 11
Nanchang 11
Naples 11
Paris 11
Redwood City 11
Totale 19.722
Salva come PNG Salva come JPEG
Nome #
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 726
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? 680
A regional approach to Antimicrobial Stewardship: the Friuli Venezia Giulia program 276
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? 226
Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia 211
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant 209
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 205
Polypharmacy in an Italian Regional Health system: a survey on drugs use in different healthcare settings 205
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 200
Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. 195
Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. 191
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients 190
Pharmacokinetic drug interaction between everolimus and antifungal triazoles in a liver transplant patient 189
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 182
Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients 181
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 180
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases 177
Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: A case report 176
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 175
Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy 174
Ceftolozane/tazobactam: place in therapy 173
Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections 172
Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function 171
- FLUCONAZOLE MONITORING IN LIVER TRANSPLANT RECIPIENTS 167
Monitoring polypharmacy in healthcare systems through a multi-setting survey: Should we put more attention on long term care facilities? 165
Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens 165
Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient 164
Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients 163
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? 163
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 162
Linezolid underexposure in a patient co-treated with venlafaxine 162
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 160
Antibiotic therapy in hematological neutropenic patients: what is the news? 160
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? 160
The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin 159
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 159
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients 158
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 158
Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. 158
Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus. 158
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions 158
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring 157
Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience 154
Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring 154
Treatment of Candida Infections with Fluconazole in Adult Liver Transplant Recipients: Is TDM-guided Dosing Adaptation Helpful? 154
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations 153
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. 152
Blood concentrations and clinical effect of cyclosporin in psoriasis 151
Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis 150
Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery 150
Antimicrobial treatment of bacterial infections in frail elderly patients: The difficult balance between efficacy, safety and tolerability 150
Effect of fluctuations of blood cyclosporine concentrations on renal function. 149
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis 149
Is MIC increase of meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae correlated with the increase of resistance rates against some other antibiotics with Gram-negative activity? 149
High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures 148
Plasma pharmacokinetics of antimicrobial agents in critically Ill patients 147
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 146
Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia 145
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp 145
Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: Proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site 145
Pharmacokinetics and drug metabolism of antibiotics in the elderly 145
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 145
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. 144
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective 144
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections 142
Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis 141
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia 141
TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients 141
Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis 141
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy 140
Pharmacokinetic-pharmacodynamic aspecte of antimicrobial prophylaxis with teisoplanin in patients undergoing major vascular surgery 140
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? 139
A Comparative Analysis of the Urinary Excretion Profiles of Mesna and Argimesna Following Oral Administration to Healthy Volunteers 139
HIV-INFECTED PATIENTS AND LIVER TRANSPLANTATION: WHO, WHEN AND WHY 138
Antimicrobial agents in elective surgery: Prophylaxis or "early therapy"? 138
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient 137
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin 137
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 136
Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia 135
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure 134
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients 132
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance 132
Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose 131
Reappraisal of Linezolid Dosing in Renal Impairment to Improve Safety 130
Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs? 130
Gentamicin once-daily in enterococcal endocarditis 129
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy 128
Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections 128
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units 128
Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report 127
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 127
The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents 127
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients 127
Daptomycin in solid organ transplantation: Consideration of dosage adjustments in renal impairment 127
Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats 126
LEVOFLOXACIN PLASMA CONCENTRATION IN CRITICALLY ILL PATIENTS 125
Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/pharmacodynamics-based approach 125
Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel 125
Effect of the number of samples on bayesian and non-linear least-squares individualization: A study of cyclosporin treatment of haematological patients with multidrug resistance 124
Procalcitonin-guided antibiotic therapy: An expert consensus 124
Totale 16.560
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.821
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.821
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021717 0 0 0 0 0 0 0 0 0 140 322 255
2021/20222.225 116 198 145 170 88 118 153 104 33 372 402 326
2022/20232.555 274 152 38 332 313 741 0 174 369 27 67 68
2023/2024668 126 53 20 10 114 79 20 57 71 40 28 50
2024/20253.674 111 318 216 126 137 198 189 253 433 281 470 942
2025/20266.944 573 860 823 575 1.105 702 1.015 266 564 461 0 0
Totale 29.704